Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

An update from Arcturus Therapeutics ( (ARCT)) is now available. On December 11, 2025, Arcturus Therapeutics announced the amicable departure of its Chief Financial Officer, Andy Sassine, effective ...

There's a lot of drone warfare footage on the internet from Ukraine and Russia. But over the last year, a surprising evolution in the conflict has emerged, via photos from the battlefront posted ...

The same optic fibers that pulse with the world’s Internet traffic are now listening to the pulse of the planet, picking up earthquake tremors in better detail than traditional seismic networks do. In ...

While most of these titles are available exclusively on the Ultimate and PC subscription tiers, there's still plenty of love being given to the lowest option, the Essential Tier. Several games from ...

The Peacekeeper MK1 is the Black Ops 7 version of the Black Ops 2 assault rifle/SMG hybrid, and it's better in 2025's entry than it ever was in BO2. Thanks to the increased maneuverability and ...

The Blue Moon Mark 1 (MK1) lunar lander is big, beautiful, and preparing to launch within the next four months. Can Blue Origin actually pull this off? Reading time 3 minutes Riding the high of its ...

View post: Walmart Is Selling a 'Heavy-Duty' $541 Carport for Only $247, and Shoppers Love Its 'Durability and Construction' At the end of last year, Boreham Motorworks announced that it would be ...

Nathan Round, part of GameRant's talented Game Guides Team, is the leading voice for Call of Duty guides. From meta loadouts to the best weapons for each season, he takes pride in crafting top-notch ...

Chipmaker Advanced Micro Devices Inc. has added to a string of recent acquisitions, buying a startup called MK1 that develops software to enhance the inference and reasoning capabilities of its ...

Fintel reports that on November 13, 2025, Citigroup maintained coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Neutral recommendation. As of November 9, 2025, the average one-year ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...